Today, the European Commission is launching an online public consultation on the Pharmaceutical Strategy for Europe.
The consultation will last three months and consists of questions which will focus on key themes: strategic autonomy and manufacturing of medicines, access to affordable medicines, innovation, and environmental sustainability and health challenges. The results of the public consultation will contribute to the preparation, in the fall, of the Pharmaceutical Strategy, which is expected to be adopted by the end of the year.
The Strategy aims to create a “future proof” system which reaps the benefits of digitalization and promotes innovation especially in areas of unmet needs, such as antimicrobials, medicines for children and medicines for rare diseases. It also intends to reduce the European Union's dependency on imports from third-countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze